Erreni M, D’Autilia F, Avigni R, Bolli E, Arnouk SM, Movahedi K, Debie P, Anselmo A, Parente R, Vincke C, van Leeuwen FWB, Allavena P, Garlanda C, Mantovani A, Doni A, Hernot S, Van Ginderachter JA. Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting. Theranostics. 2023 Jan 1;13(1):355-373. doi: 10.7150/thno.77560.
Kamal MA, Siddiqui I, Belgiovine C, Barbagallo M, Paleari V, Pistillo D, Chiabrando C, Schiarea S, Bottazzi B, Leone R, Avigni R, Migliore R, Spaggiari P, Gavazzi F, Capretti G, Marchesi F, Mantovani A, Zerbi A, Allavena P. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer. Cancers (Basel). 2022 May 27;14(11):2653. doi: 10.3390/cancers14112653.
Fernández-Mariño I, Anfray C, Crecente-Campo J, Maeda A, Ummarino A, Teijeiro-Valiño C, Blanco-Martinez D, Mpambani F, Poul L, Devalliere J, GermainM, Correa J, Fernandez-Villamarin M, Allavena P, Fernandez-Megia E, Alonso MJ, Andón FT. Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages. Drug Deliv Transl Res. 2022 Dec 6. doi: 10.1007/s13346-022-01265-9.
Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022 Nov;21(11):799-820. doi:10.1038/s41573-022-00520-5.
Allavena P, Belgiovine C, Digifico E, Frapolli R, D’Incalci M. Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment. Front Oncol. 2022 Mar 1;12:851790. doi:10.3389/fonc.2022.851790.
Mannarino L, Paracchini L, Pezzuto F, Olteanu GE, Moracci L, Vedovelli L, De Simone I, Bosetti C, Lupi M, Amodeo R, Inglesi A, Callari M, Penpa S, Libener R, Delfanti S, De Angelis A, Muzio A, Zucali PA, Allavena P, Ceresoli GL, Marchini S, Calabrese F, D’Incalci M, Grosso F. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. Int J Mol Sci. 2022 May 21;23(10):5786. doi: 10.3390/ijms23105786.
Belgiovine C, Frapolli R, Liguori M, Digifico E, Colombo FS, Meroni M, Allavena P*, D’Incalci M*. Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy. Eur J Immunol. 2021 Nov;51(11):2677-2686. doi: 10.1002/eji.202149379.
Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, Anselmo A, Ummarino A, Gandoy S, Expósito F, Redrado M, Serrano D, Calvo A, Martens M, Bravo S, Mantovani A, Allavena P*, Andón FT*. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. J Immunother Cancer. 2021 Sep;9(9):e002408. doi: 10.1136/jitc-2021-002408.
Liguori M, Digifico E, Vacchini A, Avigni R, Colombo FS, Borroni EM, Farina FM, Milanesi S, Castagna A, Mannarino L, Craparotta I, Marchini S, Erba E, Panini N, Tamborini M, Rimoldi V, Allavena P*, Belgiovine C*. The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. Cell Mol Immunol. 2021 Mar;18(3):711-722. doi: 10.1038/s41423-020-0501-0.
Digifico E, Erreni M, Colombo FS, Recordati C, Migliore R, Frapolli R, D’Incalci M, Belgiovine C, Allavena P. Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice. Cancers (Basel). 2020 Aug 1;12(8):2136. doi: 10.3390/cancers12082136.
Allavena P, Anfray C, Ummarino A, Andón FT. Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective. Clin Cancer Res. 2021 Jun 15;27(12):3291-3297. doi: 10.1158/1078-0432.CCR-20-1679.
Dacoba TG, Anfray C, Mainini F, Allavena P, Alonso MJ, Torres Andón F, Crecente-Campo J. Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors. Front Immunol. 2020 Jul 7;11:1412. doi: 10.3389/fimmu.2020.01412. eCollection 2020.
Siddiqui I, Erreni M, Kamal MA, Porta C, Marchesi F, Pesce S, Pasqualini F, Schiarea S, Chiabrando C, Mantovani A, Allavena P. Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. Oncoimmunology. 2017 Nov 1;7(2):e1388485. doi: 10.1080/2162402X.2017.1388485.
Andón FT, Digifico E, Maeda A, Erreni M, Mantovani A, Alonso MJ, Allavena P. Targeting tumor associated macrophages: The new challenge for nanomedicine. Semin Immunol. 2017 Dec;34:103-113. doi: 10.1016/j.smim.2017.09.004.
Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L,Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D’Incalci M. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205.
Marelli G, Erreni M, Anselmo A, Taverniti V, Guglielmetti S, Mantovani A, Allavena P. Hemeoxygenase- 1 Production by Intestinal CX3CR1+ Macrophages Helps to Resolve Inflammation and Prevents Carcinogenesis. Cancer Res. 2017 Aug 15;77(16):4472-4485. doi: 10.1158/0008-5472.CAN-16-2501.
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. doi: 10.1038/nrclinonc. 2016.217.
Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer. 2016 Apr 19;4:21. doi: 10.1186/s40425-016-0125-1.
Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D’Incalci M, Allavena P. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.